|
|
Article: Hemoglobin-based agent reduces need for transfusion during heart surgery.
- Article from:
- Biotech Week
- Article date:
- January 8, 2003
CopyrightCOPYRIGHT 2003 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2003 JAN 8 - (NewsRx.com & NewsRx.net) -- A phase II clinical trial conducted at Duke University Medical Center and five other U.S. institutions has shown that an agent made of purified human hemoglobin appears safe and may be effective when used instead of transfused human blood to replace blood lost during heart surgery.
If the benefits of the agent, known as hemoglobin raffimer, are proved in subsequent phase III clinical trials, physicians would not need to use as much donated blood during surgery, the researchers said. An estimated 20% of all human blood transfused in the U.S. is associated with heart surgery, so the Duke researchers believe that an efficient ...